Chronic Heart Failure With Reduced Ejection Fraction
Conditions
Keywords
HFrEF
Brief summary
This is an observational study in which data already collected from people treated with vericiguat are studied. In observational studies, only observations are made without participants receiving any advice or any changes to healthcare. Chronic heart failure with reduced ejection fraction (HFrEF) is a long-term condition that occurs when the heart is weak and cannot pump enough blood to the rest of the body with each heartbeat. This leads to a reduced supply of oxygen which the body requires to function properly. The common symptoms include breathlessness, weakness, fatigue, and swelling in the ankles and legs. If left untreated, heart failure can lead to other serious health problems, including damage to other organs, which may result in hospital stays and even death. Vericiguat works by increasing the activity of an enzyme called soluble guanylate cyclase (sGC), which relaxes the blood vessels and allows more blood to flow through. As a result, the heart is able to pump better. Vericiguat is available in Germany for the treatment of HFrEF based on the results of a study called VICTORIA. The VICTORIA study showed that vericiguat helps in lowering the chances of death or hospitalization due to heart failure. However, there is limited information available about the use of vericiguat for the treatment of HFrEF under real-world conditions in routine medical care. The main purpose of this study is to collect information about how well vericiguat works in people with HFrEF who were newly treated with vericiguat. In addition, researchers will collect information about participants' basic characteristics, including their age, gender, other health conditions they might have, and the medicines they might be taking. The data will come from 2 German health databases including people who newly started vericiguat treatment between September 2021 and September 2023.
Interventions
Vericiguat was given following routine clinical practice.
Sponsors
Bayer
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients with an initial prescription of Vericiguat (index date) according to ATC Code C01DX22. * At least 18 years or older on the initial prescription of Vericiguat.
Exclusion criteria
* No
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| All-cause mortality rates after initiation of vericiguat | Between September 2021 and September 2023 | Number of patients who died between the "Vericiguat index date" and "cohort exit" according to their death date. |
| All-cause related hospitalization rates after initiation of vericiguat | Between September 2021 and September 2023 | Sum of all fully hospitalized cases of all patients between the "Vericiguat index date" and "cohort exit". |
| Heart failure related hospitalization rates after initiation of vericiguat | Between September 2021 and September 2023 | Sum of all fully hospitalized cases with a main or secondary inpatient diagnosis according to ICD-10 GM Code I50.x or I11.0 between the "Vericiguat index date" and "cohort exit". |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Adherence of vericiguat drug use | Between September 2021 and September 2023 | Adherence will be assessed using the Medical Possession Ratio (MPR=days of supply/treatment duration). |
| Titration pattern of vericiguat drug use | Between September 2021 and September 2023 | Titration patterns will be assessed by investigating indicators such as the starting dose, the maximum dose reached as well as the time until up-titration. |
| Patient persistence of vericiguat drug use | Between September 2021 and September 2023 | Persistence will be calculated via the time until discontinuation of vericiguat. |
| Socio-demographic characteristics of patients initiating vericiguat at baseline | Between September 2021 and September 2023 | Sex and age groups. |
| Clinical characteristics of patients initiating vericiguat at baseline | Between September 2021 and September 2023 | Pre-defined comorbidities, pre-defined comedications, all-cause hospitalization, worsening hart failure event, etc. |
| Medication of interest in the 3 months before and after initiation of vericiguat | Between September 2021 and September 2023 | — |
Countries
Germany
Outcome results
None listed